

Company Registration No: 200601578E
Charity Registration No: 001961
IPC No: HEF0105/G



VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

DIRECTORS' STATEMENT
AND FINANCIAL STATEMENTS

31 DECEMBER 2015

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

31 DECEMBER 2015

CONTENTS	PAGE
Directors' Statement	1 - 2
Independent Auditors' Report	3 - 4
Statement of Financial Activities	5
Statement of Financial Position	6
Statement of Cash Flows	7
Notes to the Financial Statements	8 - 25

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

DIRECTORS' STATEMENT

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2015

The directors are pleased to present their statement together with the audited financial statements of VIVA Foundation for Children with Cancer (the "Company") for the financial year ended 31 December 2015.

In the opinion of the directors:

- (a) the financial statements as set out on pages 5 to 25 are drawn up so as to give a true and fair view of the financial position of the Company as at 31 December 2015 and the financial performance and cash flows of the Company for the financial year then ended; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

1 Directors

The directors in office at the date of this statement are:

Leong Lai Peng
Kwee Liong Keng
Koh Seow Chuan
Lee Ming San
Kay Kuok Oon Kwong
Mary Ann Wai Sheng Tsao
Tan Wah Yeow
Tan Bee Lan
Christopher Wilson (Appointed on 15 January 2015)
Cheah Kim Kee Gilbert (Appointed on 1 March 2016)

2 Directors' Interest in Shares, Debentures, Dividends and Share Options

The Company is limited by guarantee and does not have a share capital. All matters relating to the issue of shares, debentures, dividends and share options are thus not applicable.

3 Directors' Contractual Benefits

Since the end of the previous financial year, no director has received or become entitled to receive a benefit which is required to be disclosed under Section 201(8) of the Singapore Companies Act Chapter 50 by reason of a contract made by the Company or a related corporation with the director or with a firm of which he is a member, or with a company in which he has a substantial financial interest.

**VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)**


DIRECTORS' STATEMENT


FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2015

4 Independent Auditors

The independent auditors, Moore Stephens LLP, Public Accountants and Chartered Accountants, have expressed their willingness to accept re-appointment.

On behalf of the Board of Directors,


.....
Leong Lai Peng


.....
Lee Ming San

Singapore

16 MAY 2016

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF

**VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)**

We have audited the accompanying financial statements of VIVA Foundation For Children With Cancer (the "Company"), as set out on pages 5 to 25, which comprise the statement of financial position as at 31 December 2015, and statement of financial activities and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act, Chapter 50 (the "Act") and the Singapore Charities Act, Chapter 37 (the "Charities Act") and the Charities Accounting Standard, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

(cont'd)

Opinion

In our opinion, the financial statements are properly drawn up in accordance with the provisions of the Act, the Charities Act and Charities Accounting Standard, so as to give a true and fair view of the financial position of the Company as at 31 December 2015 and the financial performance, and cash flows of the Company for the year ended on that date.

Report on Other Legal and Regulatory Requirements

During the course of our audit, nothing has come to our attention that causes us to believe that during the year:

- a. The use of donation monies was not in accordance with the objectives of the Company as required under regulation 11 of the Charities (Institutions of a Public Character) Regulations; and
- b. The Company has not complied with the requirements of regulation 15 (Fund-raising expenses) of the Charities (Institutions of a Public Character) Regulations.

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.



Moore Stephens LLP
Public Accountants and
Chartered Accountants

Singapore
16 May 2016

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2015

	<u>Note</u>	<u>2015</u> S\$	<u>2014</u> S\$ Restated
<u>Unrestricted General Funds</u>			
Income			
Income from generated funds			
- Voluntary income	4	4,464,927	1,953,020
- Investment income	4	16,356	15,474
- Activities for generating funds	4	-	580,285
Income from charitable activities	5	131,388	147,921
Other income	6	22,678	587
Total income		4,635,349	2,697,287
Expenditures			
Cost of generating funds			
- Cost of generating voluntary income	7	40,269	58,832
- Fundraising activities	7	-	61,839
Charitable activities	8	4,392,563	2,233,069
Governance costs	9	792,826	751,292
Total expenditure		5,225,658	3,105,032
Net expenditure before tax expense		(590,309)	(407,745)
Tax expense	11	-	-
Net expenditure		(590,309)	(407,745)
Gross transfers between funds		-	-
Net movement in funds		(590,309)	(407,745)
Reconciliation of funds			
Total funds brought forward	20	27,118,212	27,525,957
Total funds carried forward^(a)		26,527,903	27,118,212
 (a) Total funds carried forward			
		<u>2015</u> S\$	<u>2014</u> S\$
- Available fund balance		4,717,403	4,825,712
- Donated space (Note 12) (this asset could not be monetised)		21,810,500	22,292,500
		26,527,903	27,118,212

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2015

	<u>Note</u>	<u>2015</u> S\$	<u>2014</u> S\$
Non-Current Assets			
Property and equipment	12	22,053,085	22,614,020
Current Assets			
Trade receivables	13	-	1,300
Other receivables and prepayments	14	174,002	144,180
Cash and cash equivalents	15	4,996,931	4,423,039
		5,170,933	4,568,519
Current Liabilities			
Accrued expenses	16	11,991	11,686
Deferred income	17	150,000	-
Deposits received	18	48,091	48,892
Other payables	19	486,033	3,749
		696,115	64,327
Net Current Assets		4,474,818	4,504,192
Total Assets Less Current Liabilities		26,527,903	27,118,212
Funds of Charity			
<u>Unrestricted Funds</u>			
General funds ^(a)	20	26,377,903	27,118,212
<u>Designated Funds</u>			
Designated income funds ^(b)		150,000	-
Total Charity Funds		26,527,903	27,118,212
(a) General funds		<u>2015</u> S\$	<u>2014</u> S\$
- Available fund balance		4,567,403	4,825,712
- Donated space (Note 12) (this asset could not be monetised)		21,810,500	22,292,500
		26,377,903	27,118,212

(b) Designated funds pertain to cash donation of S\$150,000 to be used for the St. Jude – VIVA Forum recognised as deferred income (Note 17).

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2015

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Cash Flows from Operating Activities		
Net expenditure before tax expense	(590,309)	(407,745)
Adjustments for:		
Non-refundable purchase tax	2,212	5,252
Depreciation of property and equipment	536,477	531,180
Gain on disposal of property and equipment	(18,027)	-
Interest income	(16,356)	(15,474)
Operating cash flows before changes in working capital	<u>(86,003)</u>	<u>113,213</u>
Trade receivables	1,300	6,120
Other receivables and prepayments	(29,822)	(17,644)
Accrued expenses	304	(10,349)
Other payables	482,285	3,749
Deferred income	150,000	(484,000)
Deposits received	(801)	2,261
Net cash flows from/(used in) operations	<u>517,263</u>	<u>(386,650)</u>
Non-refundable purchase tax paid	(2,212)	(5,252)
Net cash flows from/(used in) operating activities	<u>515,051</u>	<u>(391,902)</u>
Cash Flows from Investing Activities		
Purchase of equipment	(17,605)	(1,847)
Reimbursement for property and equipment used by third party	60,090	33,986
Interest received	16,356	15,474
Net cash flows from investing activities	<u>58,841</u>	<u>47,613</u>
Net increase/(decrease) in cash and cash equivalents	573,892	(344,289)
Cash and cash equivalents at the beginning of the year	<u>4,423,039</u>	<u>4,767,328</u>
Cash and cash equivalents at the end of the year (Note 15)	<u>4,996,931</u>	<u>4,423,039</u>

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1 General Information

VIVA Foundation for Children with Cancer (the “Company”) is a company limited by guarantee, domiciled and incorporated in Singapore. The address of the Company’s registered office and principal place of business is 8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470.

The principal activity of the Company is to fund, support and establish programmes which will improve the treatment and cure of childhood cancer. There were no significant changes in the Company’s principal activity during the financial year.

These financial statements were authorised for issue in accordance with a resolution of the Board of Directors of the Company on the date of the Directors’ Statement.

2 Significant Accounting Policies

(a) Basis of Preparation

The financial statements, which are expressed in Singapore dollars, have been prepared in accordance with the provisions of the Singapore Companies Act, Chapter 50, Charities Act, Chapter 37 (the “Act”) and Charities Accounting Standard (“CAS”). The accounting policies of the Company are consistent with the requirements of the CAS and are applied consistently to similar transactions, other events and conditions. The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with CAS requires management to exercise its judgment in the process of applying the Company’s accounting policies. It also requires the use of accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the financial year. Although these estimates are based on management’s best knowledge of current events and actions, actual results may ultimately differ from those estimates. The areas involving a higher degree of judgment or complexity are disclosed in Note 3 to the financial statements.

(b) Fund Accounting

Monies received for specific purposes, including transfers from the general fund, are credited directly to the respective fund financial statements. These include restricted funds and unrestricted funds. Restricted funds are funds held by the Company that can only be applied for specific purposes. These funds are subject to specific trusts which may be declared by the donors or with their authority or created through legal process but are still within the wider objects of the Company. Unrestricted funds are expendable at the discretion of the Company’s Board of Directors in furtherance of the Company’s objects. Designated fund is part of the unrestricted funds earmarked for a particular project. The designation is for administrative purposes only and does not restrict the Board’s discretion to apply the fund.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(b) Fund Accounting (cont'd)

Income and expenditure relating to specific funds are accounted for directly in the funds to which they relate. Assets and liabilities of the specific funds are pooled in the statement of financial position.

Funds received for specific purposes such as purchase of depreciable assets are taken to the relevant restricted fund account. The relevant fund will be reduced over the useful life of the asset in line with its depreciation. Depreciation is charged to the relevant designated funds where the asset is held.

(c) Property and Equipment

Property and equipment are initially stated at cost. Subsequent to initial recognition, property and equipment are stated at cost less accumulated depreciation. The property received for use in the form of gifts in-kind is initially stated at fair value, based on revaluation done by independent professional valuers. Such fair value is taken to statement of financial activities.

The cost of an item of property and equipment includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Irrecoverable GST allocable to property, plant and equipment and to other items shall be included in their cost where it meets the criteria for capitalisation and significant. The projected cost of dismantlement, removal or restoration is also included as part of the cost of property and equipment if the obligation for the dismantlement, removal and restoration is incurred as a consequence of acquiring or using the asset.

The cost of an item of plant and equipment is recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the cost of replacing such an item when that cost is incurred is added to the carrying amount of the item if the recognition criteria are met. The cost of day-to-day servicing of an item of plant and equipment is recognised as expenditure in the statement of financial activities in the period in which the costs are incurred. Property and equipment shall not be revalued and are not required to be assessed for impairment.

The gain or loss on the disposal of an asset shall be accounted for in net income or expenditure in the Statement of Financial Activities in the period in which the disposal occurs as the difference between the net sale proceeds and the net carrying amount of the asset.

Depreciation of an asset begins when it is available for use, i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation of an asset ceases when the asset is derecognised. Depreciation does not cease when the asset becomes idle or is retired from active use unless the asset is fully depreciated.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(c) Plant and Equipment (cont'd)

Depreciation is calculated on a straight-line basis to write off the cost (net of residual value) of the property and equipment over their estimated useful lives. The estimated useful lives are as follows:

Leasehold building	- 50 years
Renovation	- 10 years
Furniture and fixtures	- 5 years
Computer and office equipment	- 3 years

The depreciation charge for each period is recognised as expenditure in the statement of financial activities unless another section of the CAS requires it to be included in the carrying amount of another asset. The residual values, estimated useful lives and depreciation method of property and equipment are reviewed and adjusted, as appropriate, at each statement of financial position date. The effects of any revisions are recognised in the statement of financial activities for the financial year in which the changes arise. The carrying amount of the plant and equipment at the date of revision or changes is depreciated over the revised remaining useful lives.

(d) Trade and Other Receivables

Trade and other receivables, excluding prepayments, are initially recognised at their transaction price, excluding transaction costs, if any. Transaction costs are recognised as expenditure in the statement of financial activities as incurred. Prepayments are initially recognised at the amount paid in advance for the economic resources expected to be received in the future.

After initial recognition, trade and other receivables, excluding prepayments, are subsequently measured at cost less any accumulated impairment losses. Prepayments are subsequently measured at the amount paid less the economic resources received or consumed during the financial year.

Financial assets (consisting of cash and cash equivalents, and trade and other receivables) and prepayments are derecognised when the contractual rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. On derecognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received is recognised in the statement of financial activities.

Impairment

The Company assesses at each statement of financial position date whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognises an impairment loss (i.e. expenditure) immediately in the statement of financial activities when such evidence exists.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(d) Trade and Other Receivables (cont'd)

Impairment (cont'd)

To determine whether there is objective evidence that an impairment loss on financial assets has been incurred, the Company considers observable data that comes to the attention of the Company. The impairment loss is the difference between the carrying amount of the financial asset and the undiscounted future cash flows (excluding unearned interest in the case of interest-bearing assets) that the Company expects to receive from the financial asset.

The previously recognised impairment loss is subsequently reversed if the amount of the impairment loss decreases and the decrease is related objectively to an event occurring after the impairment was recognised (such as an improvement in the debtor's financial condition). The carrying amount of the asset previously impaired is increased to the extent that the new carrying amount does not exceed the amortised cost had no impairment been recognised in prior periods. The reversal of an impairment loss is recognised in the statement of financial activities.

(e) Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and at bank and fixed deposits, which are short term, highly liquid investments that are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value.

(f) Financial Liabilities

Financial liabilities are recognised on the statement of financial position when, and only when the Company became a party to the contractual provisions of the financial instrument. The Company derecognises financial liabilities when, and only when the Company's obligations are discharged, cancelled or expired.

(g) Other Payables and Accruals

Other payables, excluding accruals, are recognised at their transaction price, excluding transaction costs, if any, both at initial recognition and at subsequent measurement. Transaction costs are recognised as expenditure in the statement of financial activities as incurred. Accruals are recognised at the best estimate of the amount payable.

**VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)**

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(h) Revenue Recognition

Revenue, including donations, gifts and grants that provide core funding or are of a general nature are recognised when there is (a) entitlement (b) certainty and (c) sufficient reliability of measurement. Such income is only deferred when: the donor specifies that the grant of donation must only be used in future accounting periods; or the donor has imposed conditions which must be met before the Company has unconditional entitlement.

Donations

Revenue from donations and corporate cash sponsorships are accounted for when received, except for committed donations and corporate cash sponsorships that are recorded when the commitments are fulfilled.

Grants

Grants received to cover a particular expenditure or programme are accounted for as income upon receipt of notification of the grant award and when the criteria of entitlement, certainty and measurability are met. When conditions are attached, they must be fulfilled before the Foundation has unconditional entitlement to the income. The income is deferred as a liability where uncertainty exists as to whether the Foundation can meet the conditions and is recognised as income when there is sufficient evidence that the conditions imposed can be met.

Others

Revenue from events such as the St. Jude – VIVA Forum is recognised when the event takes place.

Interest income is recognised on a time proportion basis using the effective interest method.

(i) Gifts In Kind

A gift in kind is included in the statement of financial activities based on an estimate of the fair value at the date of the receipt of the gift of the non-monetary asset or the grant of a right to the monetary asset. The gift is recognised if the amount of the gift can be measured reliably and there is no uncertainty that it will be received.

(j) Expenditure

All expenditures are accounted for on an accrual basis and have been classified under headings that aggregate all costs related to that activity. Cost comprises direct expenditure, including direct staff costs, attributable to the activity.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(j) Expenditure (cont'd)

Cost of generating funds

The cost of generating funds are those costs attributable to generating income for the Company, other than those costs incurred in undertaking charitable activities in the furtherance of the Company's objects.

Charitable activities

Expenditure for charitable activities comprise all costs incurred in the pursuit of the charitable objects of the Company. Those costs, where not wholly attributable, are apportioned between the categories of charitable expenditure. The total costs of each category of charitable expenditure, therefore, include an apportionment of support cost, where possible.

Governance costs

Governance costs include the costs of governance arrangements, which relate to the general running of the Company as opposed to the direct management functions inherent in generating funds, service delivery and programme or project work. Expenditure on the governance of the charity will normally include both direct and related support costs which include internal and external audit, apportioned manpower costs and general costs in supporting the governance activities, legal advice for governing board members, and costs associated with constitutional and statutory requirements.

Other expenditure

Other expenditure includes the payment of any expenditure that the Company has not been able to analyse within the main expenditure categories.

(k) Employee Benefits

Defined contribution plans

Defined contribution plans are post-employment benefit plans under which the Company pays fixed contributions into separate entities such as the Central Provident Fund, and will have no legal or constructive obligation to pay further contributions if any of the funds do not hold sufficient assets to pay all employee benefits relating to employee services in the current period and preceding financial years. The Company's contributions to defined contribution plans are recognised in the financial year to which they relate.

Employee leave entitlement

Employee entitlements to annual leave and long service leave are recognised when they accrue to employees. Accrual is made for the estimated liability for annual leave and long-service leave as a result of services rendered by employees up to the statement of financial position date.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

2 Significant Accounting Policies (cont'd)

(l) Currency Translation

Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The financial statements are presented in Singapore dollars (“S\$”), which is the Company’s functional and presentation currency, as it best reflects the economic substance of the underlying events and circumstances relevant to the Company. The financial statements are presented in S\$ and all values in particular on the surplus for the year are rounded to the nearest dollar (\$) except when otherwise indicated.

(m) Income Tax

The Company is an approved charity under the Charities Act, Chapter 37 and an Institution of a Public Character under the Income Tax Act, Chapter 134. No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption.

3 Critical Accounting Estimates, Assumptions and Judgements

Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Company makes judgement, estimates and assumptions concerning the future. There are no critical judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are as follows:

Critical Accounting Estimates and Assumptions

Estimated useful lives of property and equipment

The Company’s management determines the useful lives and related depreciation charges for its property and equipment to be between 3 and 50 years. The estimate is based on the historical experience of the actual useful lives of property and equipment of a similar nature and function. Any changes to the Company’s planned use of property and equipment, could result in the actual useful lives differing from the Company’s current estimates.

In those cases where the Company determines that the useful lives of property and equipment should be shortened or extended, the Company would depreciate the net book value in excess of the estimated salvage value over the revised remaining useful lives. The carrying amount of the Company’s depreciable property and equipment as at 31 December 2015 was S\$22,053,085 (2014: S\$22,614,020).

A 10% difference in the expected useful life of these assets from management’s estimates would result in increasing or decreasing the Company’s statement of financial activities for the year by approximately S\$53,650 (2014: S\$53,120).

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

4 Income from Generated Funds

	<u>2015</u> S\$	<u>2014</u> S\$ Restated
<i>Unrestricted Funds:</i>		
<u>Voluntary income</u>		
Donations - general	2,010,602	869,786
Donations - in kind	-	5,274
	2,010,602	875,060
 <i>Designated Funds:</i>		
<u>Voluntary income</u>		
Donations - general	1,482,285	1,000,000
 Government grant:		
- Care and Share Movement Grant	972,040	77,960
	4,464,927	1,953,020
 <u>Investment income</u>		
Interest from bank balances	16,356	15,474
 <u>Activities for generating funds</u>		
Fundraising - Charity dinner	-	580,285

5 Income from Charitable Activities

	<u>2015</u> S\$	<u>2014</u> S\$
<i>Unrestricted Funds:</i>		
Registration receipt for St. Jude - VIVA Forum	131,388	147,921

6 Other Income

	<u>2015</u> S\$	<u>2014</u> S\$
<i>Unrestricted Funds:</i>		
Gain on disposal of property and equipment	18,027	-
Others	4,651	587
	22,678	587

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

7 Costs of Generating Funds

	<u>2015</u>	<u>2014</u>
	S\$	S\$
<i>Unrestricted Funds:</i>		
<u>Cost of generating voluntary income</u>		
- Non-claimable GST input tax	2,212	5,252
- Maintenance fees	37,378	53,580
- Others	679	-
	40,269	58,832
<u>Fundraising expenses</u>		
Fundraising expenses	-	61,839

8 Charitable Activities

	<u>2015</u>	<u>2014</u>
	S\$	S\$
		Restated
<i>Unrestricted Funds:</i>		
<u>Direct operating costs</u>		
Accommodation	25,834	36,378
Fellowship grants	7,600	3,604
Honoraria	10,211	9,519
Printing and publication	6,733	15,836
Transportation	57,936	68,831
Venue expense	58,411	67,643
Others	43,553	31,258
	210,278	233,069
Programme funding	4,182,285	2,000,000
	4,392,563	2,233,069

These amounts, other than the programme funding, were incurred for St. Jude - VIVA Forum held during the current financial year ended 31 December 2015.

The programme funding of S\$4,182,285 comprises:

- (a) During the current financial year, S\$2,700,000 (2014: Nil) was made to the KKH Health Endowment Fund to fund the treatment and cure for children with brain and solid tumour cancer in Singapore and the Asia Pacific region.
- (b) During the current financial year, the programme funding of S\$1,482,285 (2014: S\$1,000,000) was made to the National University of Singapore ("NUS") to support the advancement of education and research with the establishment of a Centre for Translational Research in Acute Leukaemia ("CenTRAL").
- (c) In the previous financial year, S\$1,000,000 was made to NUS to fund its cancer immunotherapy clinical research.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

9 Governance Costs

	<u>2015</u>	<u>2014</u>
	S\$	S\$
<i>Unrestricted Funds:</i>		
General and administrative expenses	30,542	48,208
Audit fees - current year	12,000	8,000
Depreciation	536,477	531,180
Professional fees	8,365	-
Salaries and related costs (Note 10)	205,442	163,904
	792,826	751,292

One (2014: Nil) staff personnel received an annual remuneration within the band of S\$100,000 to S\$150,000 during the financial year ended 31 December 2015.

All directors and other members of key management personnel do not receive any remuneration. There are no other financial services paid to the auditors of the Company.

10 Employee Benefits

	<u>2015</u>	<u>2014</u>
	S\$	S\$
<u>Salaries and related costs</u>		
Short-term employee benefits:		
- Gross salaries and bonuses	182,775	146,240
- Other staff benefits	799	602
- Post employment benefits (Defined Contribution Plans)	21,868	17,062
	205,442	163,904

The above support costs are allocated to governance costs based on time spent in governance activities and is consistent between financial years.

11 Income Tax

The Company is an approved charity under the Charities Act, Chapter 37 and an Institution of a Public Character under the Income Tax Act, Chapter 134. No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption. As required by the Charities Act (Chapter 37), the total fund-raising and sponsorship expenses of the Company for the financial year did not exceed 30% of the total gross receipts from fund-raising and sponsorship for that financial year.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

12 Property and Equipment

	<u>Leasehold building</u> S\$	<u>Computers</u> S\$	<u>Office equipment</u> S\$	<u>Furniture and fixtures</u> S\$	<u>Renovation</u> S\$	<u>Total</u> S\$
2015						
<u>Cost</u>						
At 1 January	24,100,000	9,564	1,997	7,664	430,176	24,549,401
Additions	-	17,605	-	-	-	17,605
Disposals	-	-	-	-	(60,090)	(60,090)
At 31 December	<u>24,100,000</u>	<u>27,169</u>	<u>1,997</u>	<u>7,664</u>	<u>370,086</u>	<u>24,506,916</u>
<u>Accumulated depreciation</u>						
At 1 January	1,807,500	8,117	1,732	3,194	114,838	1,935,381
Charge for the year	482,000	6,700	265	1,533	45,979	536,477
Disposal	-	-	-	-	(18,027)	(18,027)
At 31 December	<u>2,289,500</u>	<u>14,817</u>	<u>1,997</u>	<u>4,727</u>	<u>142,790</u>	<u>2,453,831</u>
<u>Net book value</u>						
At 31 December	<u>21,810,500</u>	<u>12,352</u>	<u>-</u>	<u>2,937</u>	<u>227,296</u>	<u>22,053,085</u>
2014						
<u>Cost</u>						
At 1 January	24,100,000	7,717	1,997	7,664	464,162	24,581,540
Additions	-	1,847	-	-	-	1,847
Disposals	-	-	-	-	(33,986)	(33,986)
At 31 December	<u>24,100,000</u>	<u>9,564</u>	<u>1,997</u>	<u>7,664</u>	<u>430,176</u>	<u>24,549,401</u>
<u>Accumulated depreciation</u>						
At 1 January	1,325,500	6,713	1,468	1,661	68,859	1,404,201
Charge for the year	482,000	1,404	264	1,533	45,979	531,180
At 31 December	<u>1,807,500</u>	<u>8,117</u>	<u>1,732</u>	<u>3,194</u>	<u>114,838</u>	<u>1,935,381</u>
<u>Net book value</u>						
At 31 December	<u>22,292,500</u>	<u>1,447</u>	<u>265</u>	<u>4,470</u>	<u>315,338</u>	<u>22,614,020</u>

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

12 Property and Equipment (cont'd)

The Company entered into an agreement on 10 February 2011 and received a donation of space located at 8 Sinaran Drive, 3rd level, Novena Specialist Centre, Singapore (“Community Space”). As it is a donated civic and community institution space, it cannot be monetised and rented out for profit. The leasehold building was initially carried at fair value at the statement of financial position date based on independent professional valuations by a valuer who had the appropriate qualification and recent experience in the valuation of properties in the relevant location. In determining the fair value, the valuer employed valuation techniques such as the market comparison method and estimates have been applied towards the valuation method.

An independent professional valuer, Knight Frank was engaged to determine the fair value of the leasehold building as at 31 December 2015. The independent professional valuer has, based on the comparative sales method, considered the prevailing market conditions and other relevant factors and is of the opinion that the value of the leasehold property with vacant possession is valued at S\$33.43 million as at 31 December 2015 (2014: S\$33.43 million).

13 Trade Receivables

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Third parties	-	1,300
	-	1,300

14 Other Receivables and Prepayments

	<u>2015</u>	<u>2014</u>
	S\$	S\$
<u>Other receivables</u>		
Deposits	118,678	19,769
Due from third parties	55,086	45,577
Others	196	-
	173,960	65,346
 Prepayments		
	42	78,834
	174,002	144,180

Included in deposits is an amount of S\$82,686 (2014: S\$14,477) paid for the venue for the St. Jude - VIVA Forum to be held in March 2016.

The amount due from third parties relates to the reimbursement for running costs due from Children Cancer Foundation (“CCF”), Singapore Cord Blood Bank Limited (“SCBB”) and Bone Marrow Donor Programme (“BMDP”). Under the terms stated in the licence agreements entered with the Company, CCF, SCBB and BMDP have agreed to co-share such running costs incurred for the community space which is owned by the Company. The amount due from third parties is unsecured, interest-free and repayable on demand.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

15 Cash and Cash Equivalents

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Cash on hand	106	109
Cash at bank	3,469,327	2,911,575
Fixed deposits placed with financial institutions	1,527,498	1,511,355
	4,996,931	4,423,039

The effective interest rate on the interest earning bank balance is 0.54% per annum (2014: 0.99%).

The interest rate earned on fixed deposits is at 0.64% to 1.39 % (2014: 0.64% to 0.94%) per annum with maturity dates ranging from 3 to 6 months (2014: 3 to 6 months).

16 Accrued Expenses

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Accruals	5,510	11,686
GST payable	6,481	-
	11,991	11,686

17 Deferred Income

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Third party	150,000	-

In 2015, the Company received S\$150,000 deferred income which the donor specified is to be used for the St. Jude - VIVA Forum which will be held in the financial year ending 31 December 2016.

18 Deposits Received

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Third parties	48,091	48,892

As at 31 December 2015, the Company has received deposits of S\$48,091 (2014: S\$48,892) in relation to the terms stated in the licence agreements entered with Children Cancer Foundation (“CCF”), Singapore Cord Blood Bank Limited (“SCBB”) and Bone Marrow Donor Programme (“BMDP”).

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

19 Other Payables

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Third party	482,285	-
Others	3,748	3,749
	486,033	3,749

The amount due to a third party relates to a donation received from Singapore Totalisator Board to reimburse the expenditure incurred by the CentRAL.

20 Funds of Charity

	<u>2015</u>	<u>2014</u>
	S\$	S\$
<i>Unrestricted Funds</i>		
General fund		
- Available fund balance	4,717,403	4,825,712
- Donated space (Note 12)		
(this asset cannot be monetised)	21,810,500	22,292,500
	26,527,903	27,118,212

Movements of the funds during the current and previous financial year are disclosed as follows:

	<u>Unrestricted Funds</u> S\$
Funds balance at 1 January 2015	27,118,212
Total income	4,635,349
Total expenditure	(5,225,658)
Net expenditure	(590,309)
Funds balance at 31 December 2015	26,527,903
Funds balance at 1 January 2014	27,525,957
Total income	2,697,287
Total expenditure	(3,105,032)
Net expenditure	(407,745)
Funds balance at 31 December 2014	27,118,212

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

21 Tax Exempt Receipts

The Company enjoys a concessionary tax treatment whereby qualifying donors are granted a 3 times (2014: 2.5 times) tax deduction for the donations made to the Company.

	<u>2015</u>	<u>2014</u>
	S\$	S\$
Tax exempt receipts issued for donations collected	<u>1,864,804</u>	<u>1,337,576</u>

22 Other Charity Funds

The Company held donation drives to raise funds for specific projects indicated in (i), (ii), (iii) and (iv). The donations raised and expended in respect of these specific projects are shown below.

The donations contributed by the donors were designated for specific purposes and the money was paid directly to the beneficiaries. Therefore, these donations and the amounts expended below are not reflected in the financial statements of the Company.

	<u>Donations Received</u>	<u>Government Matching grant</u>
	S\$	S\$
<u>31 December 2015</u>		
National University of Singapore		
- Children Cancer Centre Fund (“CCCEF”) ⁽ⁱ⁾		
Balance at 1 January	1,573,172	2,925,808
<u>Add:</u>		
Investment income	14,460	254,984
Other income	1,746	-
Balance at 31 December	<u>1,589,378</u>	<u>3,180,792</u>
National University Hospital		
- Health Research Endowment Fund (“HREF”) ⁽ⁱⁱ⁾		
Balance at 1 January	2,879,444	3,000,000
<u>Add/(Less):</u>		
Other income	51,453	-
Expenditure	(297,588)	-
Balance at 31 December	<u>2,633,309</u>	<u>3,000,000</u>

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

22 Other Charity Funds (cont'd)

	<u>Donations Received</u>	<u>Government Matching grant</u>
<u>31 December 2015 (cont'd)</u>		
National University of Singapore		
- VIVA Paediatric Oncology Fund ("VPOF")⁽ⁱⁱⁱ⁾		
Balance at 1 January	5,825,549	17,089,829
<u>Add/(Less):</u>		
Investment income	-	1,488,710
Other income	19,744	-
Expenditure	(1,232,104)	(77,477)
Balance at 31 December	4,613,189	18,501,062
National University of Singapore		
- Education and Research Fund ("ERF")^(iv)		
Balance at 1 January	-	934,378
<u>Add/(Less):</u>		
Investment income	-	81,431
Balance at 31 December	-	1,015,809
<u>31 December 2014</u>		
National University of Singapore		
- Children Cancer Centre Fund ("CCCEF")⁽ⁱ⁾		
Balance at 1 January	1,564,086	2,652,999
<u>Add:</u>		
Investment income	9,086	272,809
Balance at 31 December	1,573,172	2,925,808
National University Hospital		
- Health Research Endowment Fund ("HREF")⁽ⁱⁱ⁾		
Balance at 1 January	3,188,403	3,000,000
<u>Add/(Less):</u>		
Other income	5,277	-
Expenditure	(314,236)	-
Balance at 31 December	2,879,444	3,000,000

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

22 Other Charity Funds (cont'd)

	Donations Received S\$	Government Matching grant S\$
<u>31 December 2014 (cont'd)</u>		
National University of Singapore		
- VIVA Paediatric Oncology Fund ("VPOF") ⁽ⁱⁱⁱ⁾		
Balance at 1 January	7,226,379	15,517,821
<u>Add/(Less):</u>		
Other income	15,708	1,595,727
Expenditure	(1,416,538)	(23,719)
Balance at 31 December	5,825,549	17,089,829
 National University of Singapore		
- Education and Research Fund ("ERF") ^(iv)		
Balance at 1 January	-	918,388
<u>Add/(Less):</u>		
Investment income	-	15,990
Balance at 31 December	-	934,378

- (i) Children Cancer Centre - The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as the VIVA-University Children’s Cancer Centre (VUC³) at the National University Hospital which will be the centre of excellence for the treatment and cure of childhood cancer particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by VIVA Foundation with S\$822,000 of non-asset items and by Singapore Totalisator Board with a maximum of up to S\$4.2 million.
- (ii) Health Research Endowment Fund - The funds were donated to the National University Hospital to establish the Mrs. Lee Kong Chian Memorial Chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the VIVA Children’s Cancer Program. The donation of S\$3 million was received from Lee Foundation, via VIVA Foundation and was matched by the Ministry of Health with S\$3 million in two payments received December 2006 and March 2007. The money was used as a bridging loan to support the setting up for VIVA University Children’s Cancer Centre.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2015

22 Other Charity Funds (cont'd)

- (iii) VIVA Paediatric Oncology Fund – The VIVA Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with a matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund shall be used to advance paediatric oncology including, but not limited to, supporting the VIVA University Children’s Cancer Centre and St Jude VIVA Children’s cancer program. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish for strategic research programs in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone Cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.
- (iv) Education and Research Fund – The funds were donated by the Company to National University of Singapore, Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the VIVA Children’s Cancer Programme and income and expenses for Annual ST Jude VIVA Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Company.

23 Comparative Figures

Certain comparative figures have been restated to recognise the donation of S\$1 million received from Children’s Cancer Foundation and the programme funding of S\$1 million made to NUS to support the advancement of education and research of the establishment of CENTRAL. A summary of such restatement is as follows:

	Previously <u>reported</u> 2014 S\$	<u>Restated</u> 2014 S\$
<u>Statement of financial activities</u>		
Income from generated funds		
- Voluntary income	953,020	1,953,020
Expenditures		
- Charitable activities	1,233,069	2,233,069

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

THE FOLLOWING SUPPLEMENTARY NOTES
HAVE BEEN PREPARED FOR MANAGEMENT PURPOSES ONLY
AND DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

A. INCOME & EXPENDITURE

	Matching Grants									
	Booked in the accounts of					Booked in the accounts of				
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
	VIVA	NUS- CCCEF	NUH- HREF	NUS- VPOF	NUS- ERF	NUS- CCCEF	NUH- HREF	VIVA VPOF	VIVA- ERF	VIVA- PPO
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
31 December 2015										
Balance as of 1 January 2015, net	27,118	1,573	2,879	5,825	-	2,926	3,000	11,187	934	5,903
Income										
1 January 2015 to										
31 December 2015	4,635	16	51	20	-	255	-	975	81	513
Expenditure										
1 January 2015 to										
31 December 2015	(5,225)	-	(297)	(1,232)	-	-	-	-	-	(77)
Refund										
1 January 2015 to										
31 December 2015	-	-	-	-	-	-	-	-	-	-
Balance as of 31 December 2015	26,528	1,589	2,633	4,613	-	3,181	3,000	12,162	1,015	6,339

- (1) VIVA Foundation for Children with Cancer
(2) & (6) National University of Singapore - Children Cancer Centre Fund
(3) & (7) National University Hospital - Health Research Endowment Fund
(4) & (8) National University of Singapore - VIVA Paediatric Oncology Fund
(5) & (9) National University of Singapore - Education and Research Fund
(10) VIVA - Professorship in Paediatric Oncology

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

A. INCOME & EXPENDITURE (cont'd)

	Total Funds Received	
	(11) =	(12) =
	(1)+(2)+(3)+(4)+(5)	(6)+(7)+(8)+(9)+(10)
	Direct	Matching
	S\$'000	S\$'000
Income		
Balance as of		
1 January 2015, Gross	58,855	23,977
1 January 2015 to		
31 December 2015	4,722	1,824
Balance as of 31 December 2015	63,577	25,801

	(i) To Dec 15 S\$'000
Details of income booked in VIVA's accounts	
Charitable activities (i.e. St. Jude - VIVA Forum)	131
Voluntary income	4,465
Activities for generating funds	-
Investment income	16
Others	23
Total income	4,635

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

A. INCOME & EXPENDITURE (cont'd)

	Booked in the accounts of		Matching Grants Booked in the accounts of							
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
	VIVA S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	NUS- VPOF S\$'000	NUS- ERF S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	VIVA VPOF S\$'000	VIVA- ERF S\$'000	VIVA- PPO S\$'000
31 December 2014										
Balance as of 1 January 2014, net Income	27,526	1,564	3,188	7,226	-	2,653	3,000	10,144	918	5,374
31 December 2014	2,697	9	5	16	-	273	-	1,043	16	553
Expenditure	(3,105)	-	(314)	(1,417)	-	-	-	-	-	(24)
Refund	-	-	-	-	-	-	-	-	-	-
Balance as of 31 December 2014	27,118	1,573	2,879	5,825	-	2,926	3,000	11,187	934	5,903

- (1) VIVA Foundation for Children with Cancer
(2) & (6) National University of Singapore - Children Cancer Centre Fund
(3) & (7) National University Hospital - Health Research Endowment Fund
(4) & (8) National University of Singapore - VIVA Paediatric Oncology Fund
(5) & (9) National University of Singapore - Education and Research Fund
(10) VIVA - Professorship in Paediatric Oncology

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

A. INCOME & EXPENDITURE (cont'd)

		(11) =	Total Funds Received	(12) =
		(1)+(2)+(3)+(4)+(5)	(6)+(7)+(8)+(9)+(10)	
	Direct		Matching	
	S\$'000		S\$'000	
Income	Balance as of			
	1 January 2014, Gross	56,128		22,092
	1 January 2014 to			
	31 December 2014	2,727		1,885
Balance as of 31 December 2014		58,855		23,977

Details of income booked in VIVA's accounts

	(i)
	To Dec 14
	S\$'000
Charitable activities (i.e. St. Jude - VIVA Forum)	148
Voluntary income	1,953
Activities for generating funds	580
Investment income	15
Others	1
Total income	2,697

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

B. PLEDGES RECEIVABLE

	To be booked in the accounts of				Matching Grants To be booked in the accounts of				
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
VIVA		NUS- CCCEF	NUH- HREF	NUS- VPOF	NUS- ERF	NUS- CCCEF	NUH- HREF	NUS- VPOF	NUS- ERF
S\$'000		S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance as of 1 January 2015	-	-	-	-	-	-	-	-	-
Pledges written off	-	-	-	-	-	-	-	-	-
Total pledges receivable	-	-	-	-	-	-	-	-	-

31 December 2015

Balance as of 1 January 2015
Pledges written off
Total pledges receivable

$$\begin{aligned} \text{Total Funds Received} \\ (10) = & (11) = \\ & (6)+(7)+(8)+(9) \\ \text{Direct} & \text{Matching} \\ \text{S\$'000} & \text{S\$'000} \end{aligned}$$

Balance as of 1 January 2015	-	-
Pledges written off	-	-
Total pledges receivable	-	-

- (1) VIVA Foundation for Children with Cancer
(2) & (6) National University of Singapore - Children Cancer Centre Fund
(3) & (7) National University Hospital - Health Research Endowment Fund
(4) & (8) National University of Singapore - VIVA Paediatric Oncology Fund
(5) & (9) National University of Singapore - Education and Research Fund

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

B. PLEDGES RECEIVABLE (cont'd)

(1)	To be booked in the accounts of			Matching Grants To be booked in the accounts of				
	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
VIVA S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	NUS- VPOF S\$'000	NUS- ERF S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	NUS- VPOF S\$'000	NUS- ERF S\$'000
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-

31 December 2014

Balance at of 1 January 2014

Pledges written off

Total pledges receivable

Total Funds Received	
(10) =	(11) =
(1)+(2)+(3)+(4)+(5)	(6)+(7)+(8)+(9)
Direct	Matching
S\$'000	S\$'000

Balance as of 1 January 2014

Pledges written off

Total pledges receivable

- | | |
|-----------|--|
| (1) | VIVA Foundation for Children with Cancer |
| (2) & (6) | National University of Singapore - Children Cancer Centre Fund |
| (3) & (7) | National University Hospital - Health Research Endowment Fund |
| (4) & (8) | National University of Singapore - VIVA Paediatric Oncology Fund |
| (5) & (9) | National University of Singapore - Education and Research Fund |

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

C. TOTAL AMOUNTS RAISED

	Year ended 31 December 2015	Year ended 31 December 2014
	S\$'000	S\$'000
Received		
- Direct	4,722	2,727
- Matching	1,824	1,885
	6,546	4,612
Pledges receivable		
- Direct	-	-
- Matching	-	-
	-	-
Total	6,546	4,612

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2015

D. RESOURCES AVAILABLE

	As at 31 Dec 2015	As at 31 Dec 2014	Total	Expendable	Non-Expendable	Total
	(Matching Grant)	(Matching Grant)	S\$'000	S\$'000	S\$'000	S\$'000
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
(i) RECEIVED						
Own account	26,528	-	26,528	27,118	-	27,118
NUS-CCEF	1,589	3,181	4,770	1,573	2,926	4,499
NUH-HREF	2,633	3,000	5,633	2,879	3,000	5,879
VIVA-POF	4,613	12,162	16,775	5,825	11,187	17,012
VIVA-ERF	-	1,015	1,015	-	934	934
VIVA-PPO	-	6,339	6,339	-	5,903	5,903
	35,363	25,697	61,060	37,395	23,950	61,345
(ii) PLEDGES RECEIVABLE						
Own account	-	-	-	-	-	-
NUS-CCEF	-	-	-	-	-	-
NUH-HREF	-	-	-	-	-	-
NUS-VPOS	-	-	-	-	-	-
NUS-ERF	-	-	-	-	-	-
	-	-	-	-	-	-
TOTAL (i) + (ii)						
Own account	26,528	-	26,528	27,118	-	27,118
NUS-CCEF	1,589	3,181	4,770	1,573	2,926	4,499
NUH-HREF	2,633	3,000	5,633	2,879	3,000	5,879
VIVA-POF	4,613	12,162	16,775	5,825	11,187	17,012
VIVA-ERF	-	1,015	1,015	-	934	934
VIVA-PPO	-	6,339	6,339	-	5,903	5,903
	35,363	25,697	61,060	37,395	23,950	61,345